Study of Semaglutide Injections to Prevent Type 2 Diabetes in Women with Recent Gestational Diabetes and Glucose Intolerance
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2026-09-15
252
Participants Needed
13
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying women with a recent history of gestational diabetes GDM who have persistent glucose intolerance shortly after giving birth. These women are at high risk of developing type 2 diabetes T2DM, with about half developing it within five years. The study aims to evaluate whether using semaglutide, a long-acting GLP-1 agonist, can reduce the long-term risk of developing T2DM compared to placebo. This study is a phase 3, double-blind, randomized controlled trial conducted in multiple centers.
Participants are randomly assigned to receive either semaglutide or a placebo once weekly by injection, alongside lifestyle measures. The semaglutide dose is gradually increased over eight weeks to a maintenance dose of 1 mg per week. The treatment period can last up to three years. After stopping the intervention, participants will undergo a 75g oral glucose tolerance test OGTT 3 to 6 months later. Randomization considers body mass index categories at early postpartum.
Throughout the study, participants will have regular assessments including blood tests for glucose, HbA1c, insulin sensitivity, and beta-cell function. Researchers will also measure body weight, body composition, blood pressure, heart rate, lipid profiles, and metabolic syndrome prevalence. Patient-reported outcomes such as quality of life, depression, anxiety, treatment satisfaction, sleep quality, and food security will be collected. Health economic measures and biomarker analyses will also be performed. The primary outcome is the development of type 2 diabetes by 160 weeks, with continued follow-up up to 184 weeks.
CONDITIONS
Brief Title
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
Research Team
K
Katrien Benhalima, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
History of gestational diabetes diagnosed by 2013 WHO criteria during or before 24 weeks gestation
Diagnosed with prediabetes between 6 weeks and 12 months postpartum by ADA criteria (impaired fasting glucose, impaired glucose tolerance, or HbA1c 5.7-6.4%)
Breastfeeding stopped
No intention to become pregnant within the next year
Using effective contraception
No use of medication affecting glucose metabolism
Signed informed consent form before any study procedure
You will not qualify if you...
Diagnosed with established diabetes
Presence of autoantibodies suggesting type 1 diabetes
Normal glucose tolerance
History of pancreatitis
Previous bariatric surgery or planned bariatric surgery within two years
Inability to understand or speak Dutch, French, or English
Currently pregnant or planning pregnancy within one year after study participation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 3 years
Participants receive weekly injections of semaglutide or placebo with a gradual dose increase over eight weeks, alongside lifestyle measures. Treatment lasts up to three years.
Regular visits throughout treatment
Follow-up
Duration - 3 to 6 months
After stopping the study medication, participants undergo a glucose tolerance test 3 to 6 months later and have assessments of blood sugar, body weight, insulin function, and quality of life.
1 to 2 visits after treatment ends
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.